Opus Genetics, Inc. quarterly report, Q2 FY2016

Business context and reporting period

Filing identity mismatch: The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended June 30, 2016—not an Opus Genetics, Inc. filing. The summary below reflects the filing provided.

Rexahn is a clinical-stage oncology biopharmaceutical company with no commercial product revenue. Its principal candidates are Archexin, RX-3117 and Supinoxin; it also has preclinical programs. The financial statements are unaudited.

Financial performance and position

At June 30, 2016, cash and cash equivalents were $7.88 million and marketable securities were $11.52 million. Current assets were $20.39 million versus current liabilities of $4.72 million, including $2.34 million of warrant liabilities. Total assets were $20.53 million and stockholders’ equity was $15.81 million. The balance sheet presents no conventional borrowings. No operating margin is meaningful because the company had no revenue.

Material changes versus prior comparable periods

• Second-quarter net loss narrowed from $3.23 million in 2015 to $1.77 million in 2016; first-half net loss narrowed from $7.51 million to $5.91 million.
• R&D expense declined 30.9% in the quarter and 6.9% in the first half, primarily because drug manufacturing costs were lower. G&A increased 5.7% in the quarter, mainly due to recruiting costs, and declined 1.2% for the first half.
• First-half operating cash use rose slightly from $8.44 million in 2015 to $8.61 million in 2016. Cash and cash equivalents fell $2.32 million from year-end 2015.
• A March 2016 registered offering generated $5.0 million gross proceeds ($4.58 million net cash from financing activities), issuing 15.625 million shares and warrants to purchase up to 11.719 million shares.

Outlook, risks and unusual items

• Management stated that cash, cash equivalents and marketable securities were expected to fund current activities for at least 12 months. It also said additional capital would be needed to continue development; if financing is unavailable, R&D activity may have to be reduced.
• Management expected expenses to rise in the remainder of 2016 compared with the second quarter, citing increased clinical-trial enrollment and planned manufacturing campaigns. No numerical earnings or revenue guidance was provided.
• First-half results included a $2.97 million noncash unrealized gain from revaluing warrant liabilities, compared with $1.67 million in the prior-year period. This gain reduced reported net loss; it primarily reflected the lower share price and is subject to significant valuation assumptions.
• R&D vendor agreements had an estimated $6.44 million cost to complete at June 30, 2016; the agreements may be terminated with appropriate notice. Clinical development, regulatory approvals, third-party research providers and future financing are key risks.
• The company reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter. It reported no material change to previously disclosed risk factors.

Important facts for investors to verify

• Confirm the issuer: this document identifies Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
• Review the March 2016 offering terms and potential dilution from the 12.5 million warrants issued in the offering, as well as the 38.99 million total warrants outstanding at quarter-end.
• Assess whether the stated 12-month liquidity runway remains adequate given operating cash use, planned trial activity and manufacturing costs.
• Track trial progress and spending for Archexin, RX-3117 and Supinoxin, including the anticipated increase in R&D expenses.
• Distinguish noncash warrant revaluation gains from operating performance and cash generation.